Ignite Creation Date:
2024-10-25 @ 8:02 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06538272
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
None
First Post:
2024-07-24
Brief Title:
Study to Investigate the Chemotherapy-Induced Peripheral Neuropathy CIPN Onset-Suppressing Effect and Safety of ONO-2910 in Patients With Breast Cancer Receiving Weekly Paclitaxel
Sponsor:
None
Organization:
None
Study Overview
Official Title:
An Early Phase II Multicenter Placebo-Controlled Randomized Double-Blind Parallel-Group Comparison Study to Investigate the Chemotherapy-Induced Peripheral Neuropathy CIPN Onset-Suppressing Effect and Safety of ONO-2910 in Patients With Breast Cancer Receiving Weekly Paclitaxel
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To investigate the safety and CIPN onset-suppressing effect of ONO-2910 in participants receiving paclitaxel PTX weekly as chemotherapy for breast cancer in Japan
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None